Gout, a painful joint condition, is on the rise globally, affecting even younger individuals. This surge is linked to ageing ...

For anyone unfamiliar with gout - and I envy you - it’s a condition that announces itself with all the subtlety of a fire ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

The burden of cardiovascular-kidney-metabolic (CKM) comorbidities among adults with gout is high, noted Chio Yokose, MD, MSc, ...

For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...

Global study reveals alarming rise in gout cases among young people aged 15 to 39, with rates increasing 66% from 1990 to ...

Patients with gout who receive 5 years of treat-to-target urate-lowering therapy achieve reductions in serum urate levels, ultrasound-detected crystal deposits, and disease flares.

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Toe and foot pain are no joke — they can be very uncomfortable and affect your everyday activities. Gout and turf toe are two conditions that can cause pain and swelling of your big toe and its joints ...

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.